British AstraZeneca starts production of COVID-19 vaccine without finishing the testing

British-Swedish pharmaceutical company AstraZeneca, which is working on a vaccine against coronavirus, has begun its production, according to the Guardian.

The publication specifies that the company, working together with the University of Oxford, began production of the vaccine even before the end of testing and approval by regulatory authorities.

“According to our current calculations, the data will arrive by the end of summer, by August, so we will know in September whether we have the vaccine or not,” said Pascal Sorio, CEO of AstraZeneca.

AstraZeneca announced this week that it is collaborating with the Coalition for Epidemic Preparedness Innovation (CEPI), the Global Alliance for Vaccines and Immunization (GAVI) and the India Serum Institute to increase the production of a potential vaccine to 2 billion doses.




Sorio said the company has also established separate production lines for the vaccine in the U.S., Europe, and India and plans similar steps in China. He added that the work on the vaccine is carried out on a non-commercial basis so that if the company fails, it risks losses.

According to The Guardian, Oxford University began testing the vaccine with hundreds of volunteers back in April, and so far the number of participants has reached 1,000. At the same time, the university announced in May that it had made significant progress. In addition, researchers reported that in mid-June, trials will begin in Brazil, the country that has reached the second place in the world in terms of the number of infected with coronavirus (615,870 people).

Leave a Reply